Compare Royal Caribbean Cruises Ltd (RCL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs 10X Genomics Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $261.61 (market cap $70.74B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 8.3× 10X Genomics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.27% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RCL | TXG | |
|---|---|---|
Market Cap | $70.74B | $8.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.23 | $67.29 |
52-Week Low | $246.71 | $11.34 |
Enterprise Value | $93.38B | $8.08B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with technical indicators showing a bearish trend near key support at $261. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.21 vs. $3.98, revenue growth to $17.93B in 2025, and robust profitability margins. Recent news highlights dividend declarations and institutional buying interest despite oil price concerns impacting cruise stocks.
The outlook remains positive with analyst consensus price target of $367.83 suggesting 39% upside, supported by earnings momentum and institutional accumulation. Key risks include oil price volatility affecting fuel costs and competitive pressures in the cruise industry. The stock presents a growth opportunity with solid fundamentals but requires monitoring of macroeconomic headwinds.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
